Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02738125
Other study ID # P15-681
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 29, 2016
Est. completion date April 29, 2029

Study information

Verified date June 2023
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study assesses the long?term effectiveness of adalimumab in subjects starting a treatment for ulcerative colitis in real life conditions, namely to describe the time to loss of clinical benefit in a time to event approach.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 265
Est. completion date April 29, 2029
Est. primary completion date April 29, 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Suffering from ulcerative colitis - Naïve from Adalimumab - Starting a treatment with adalimumab - Capable of and willing to grant authorization for use/disclosure of data collected - Able to read, understand, and complete patients questionnaires Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Centre Medical Alexandre Dumas /Id# 165857 Amiens
France Duplicate_Hopital Robert Ballanger /ID# 151382 Aulnay Sous Bois Cedex
France CH Henri Duffaut /ID# 151383 Avignon CEDEX 9 Provence-Alpes-Cote-d Azur
France CH Henri Duffaut /ID# 151499 Avignon CEDEX 9 Provence-Alpes-Cote-d Azur
France Cabinet Medical /ID# 155460 BAIE Mahault Guadeloupe
France Centre Hospitalier de la Cote /ID# 163714 Bayonne Pyrenees-Atlantiques
France Polyclinique du Tondu /ID# 161977 Bordeaux
France Centre Endo Nord Isere /ID# 151390 Bourgoin Jallieu
France Geier, Cabinet Medical /ID# 149652 Brest
France Hopital de la Cavale Blanche /ID# 152618 Brest
France Hopital de la Cavale Blanche /ID# 153608 Brest
France Cabinet Medical /ID# 151391 Caen
France CHRU Tours - Hopital Trousseau /ID# 163503 Chambray Les Tours
France Pole Sante Leonard de Vinci /ID# 151384 Chambray Les Tours
France CH du Haut Anjou /ID# 151151 Chateau Gontier
France Ch Chauny /Id# 151149 Chauny
France CHU Clermont-Ferrand /ID# 153527 Clermont Auvergne-Rhone-Alpes
France Hopital Beaujon /ID# 151498 Clichy Ile-de-France
France Hopital Louis Mourier,Colombes /ID# 152650 Colombe
France GHPSO CH Creil /ID# 151117 Creil
France Centre Hosp Intercommunal de Creteil /ID# 152361 Creteil Val-de-Marne
France Cabinet Medical /ID# 150978 Douarnenez
France Cabinet Medical /ID# 150845 Erstein
France Centre Gastro Loire /ID# 151387 Gien
France Clinique du Palais /ID# 151175 Grasse
France CH La Rochelle - Hopital Saint Louis /ID# 151182 La Rochelle
France CHU Grenoble - Hopital Michallon /ID# 151508 La Tronche
France CHRU Lille - Hopital Claude Huriez /ID# 151514 Lille Hauts-de-France
France Duplicate_HOPITAL DUPUYTREN /ID# 157889 Limoges
France CH Des Deux Vallees Longumeau /ID# 150977 Longjumeau
France Centre des consultations spécialisées de la sauvegarde /ID# 151515 Lyon
France HCL - Hopital Edouard Herriot /ID# 151513 Lyon
France APHM - Hopital Nord /ID# 152620 Marseille Bouches-du-Rhone
France Hopital Saint Joseph /ID# 164405 Marseille Bouches-du-Rhone
France Centre Medical Les Sources /ID# 151174 Montigny Les Cormeilles
France Chu de Nice-Hopital L'Archet Ii /Id# 151132 Nice Alpes-Maritimes
France Chu de Nice-Hopital L'Archet Ii /Id# 151181 Nice Alpes-Maritimes
France CHU NIMES - Hopital Caremeau /ID# 169178 Nimes CEDEX 9 Gard
France AP-HP - Hopital Bichat - Claude-Bernard /ID# 151176 Paris
France AP-HP - Hopital Saint-Louis /ID# 151509 Paris
France Cabinet Medical /ID# 151118 Paris
France Cabinet Medical /ID# 152362 Paris
France Hopital Paris Saint-Joseph /ID# 153526 Paris
France Duplicate_CHU LYON SUD /ID# 153801 Pierre Benite
France HCL - Hôpital Lyon Sud /ID# 151146 Pierre Benite CEDEX Auvergne-Rhone-Alpes
France HCL - Hôpital Lyon Sud /ID# 151505 Pierre Benite CEDEX Auvergne-Rhone-Alpes
France HCL - Hôpital Lyon Sud /ID# 165859 Pierre Benite CEDEX Auvergne-Rhone-Alpes
France Cabinet Medical /ID# 151092 Plerin
France Cabinet Medical /ID# 151093 Plerin
France Cabinet Medical /ID# 151094 Plerin
France Cabinet Medical /ID# 151148 Poissy
France Cabinet Medical /ID# 151555 Prades-le-lez
France CH Annecy Genevois Site Annecy /ID# 151131 PRINGY cedex Haute-Savoie
France CHRU Pontchaillou /ID# 166806 Rennes
France CHU La Réunion - site St Denis - Félix-Guyon /ID# 151556 Saint-Denis
France CHU d'Amiens /ID# 152651 Salouel
France Cabinet Medical /ID# 151558 Saverne
France Centre de Consultations /ID# 151128 St Nazaire
France Centre de Consultations /ID# 151164 St Nazaire
France Centre de Consultations /ID# 155458 St Nazaire
France Cabinet Medical /ID# 151559 St Quentin
France CHU de SAINT ETIENNE - Hopital Nord /ID# 166807 St. Priest En Jarez Loire
France Cabinet Medical /ID# 151162 Strasbourg
France Centre Medical du Clos de Pacy /ID# 151129 Sucy En Brie
France Maison de Santé Protestante Bordeaux Bagatelle /ID# 151497 Talence CEDEX
France Cabinet Medical, Dr. Constant, /ID# 151119 Toulon
France Cabinet Medical /ID# 152841 Toulouse
France Cabinet Medical /ID# 170136 Toulouse
France CHU Toulouse - Hopital Rangueil /ID# 157890 Toulouse
France Clinique Ambroise Pare /ID# 161978 Toulouse
France Clinique Pasteur /ID# 151088 Toulouse CEDEX 3
France Clinique Pasteur /ID# 155792 Toulouse CEDEX 3
France CHU Toulouse - Hopital Purpan /ID# 167179 TOULOUSE Cedex 9 Haute-Garonne
France Duplicate_Hopital Trousseau /ID# 150168 Tours
France Cabinet Medical /ID# 151557 Troyes
France CHRU Nancy - Hôpitaux de Brabois /ID# 151147 Vandœuvre-lès-Nancy Meurthe-et-Moselle
France GH Mutualiste Les Portes Du Sud /ID# 152374 Venissieux
France GH Mutualiste Les Portes Du Sud /ID# 159231 Venissieux
France Centre Hépato-Biliaire - Hopital Paul-Brousse /ID# 151152 Villejuif
France Cabinet Medical /ID# 152617 Voiron

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to loss of clinical benefit Loss of clinical benefit will be defined as one of the following: loss of efficacy leading to adalimumab discontinuation or introduction/reinforcement of aminosalicylates, 6-mercaptopurine, or azathioprine, introduction or reinforcement of corticosteroids (any route), UC-related surgery, discontinuation of adalimumab due to adverse event, death. Up to Month 120
Secondary Change from Baseline (Month 0) in Steroid-free remission Steroid- free remission is defined as partial Mayo score <= 2 with no subscore >1 and no daily intake of prednisone. From Month 0 to Month 120
Secondary Change from Baseline (Month 0) in Clinical Remission Clinical remission is defined as partial Mayo score <= 2 with no subscore >1 From Month 0 to Month 120
Secondary Change from Baseline (Month 0) in Clinical Response Clinical response is decrease in partial Mayo score >= 3 points and >= 30% from baseline plus a decrease in rectal bleeding subscore >= 1 or an absolute rectal bleeding subscore <= 1. From Month 0 to Month 120
See also
  Status Clinical Trial Phase
Completed NCT02819635 - A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) Phase 2/Phase 3
Not yet recruiting NCT05960864 - Chinese Spondyloarthritis Inception Cohort (CESPIC)
Not yet recruiting NCT05316220 - A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Phase 3
Completed NCT02345733 - Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Phase 4
Terminated NCT02217722 - Use of the Ulcerative Colitis Diet for Induction of Remission N/A
Completed NCT02778464 - Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease
Completed NCT01971814 - Early Serum Infliximab Levels in Severe Ulcerative Colitis. Phase 1
Completed NCT03223012 - Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
Active, not recruiting NCT03456206 - Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Completed NCT04254783 - A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Phase 1
Completed NCT03398148 - A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Withdrawn NCT02087878 - A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
Completed NCT02065622 - Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis Phase 3
Completed NCT03695185 - A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy Phase 2
Completed NCT02108821 - Fecal Microbiota Transplantation in Pediatric Patients Phase 1
Terminated NCT03758443 - Efficacy & Safety of TD-1473 in Ulcerative Colitis Phase 2/Phase 3
Completed NCT01364896 - Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Terminated NCT03920254 - TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study Phase 2/Phase 3
Recruiting NCT01277419 - German Spondyloarthritis Inception Cohort
Recruiting NCT05377580 - A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis Phase 2

External Links